Andres Gutiérrez
Chief Tech/Sci/R&D Officer chez ADVAXIS, INC.
Fortune : 30 $ au 31/03/2024
Profil
Andres A.
Gutiérrez is currently the Chief Medical Officer at Old Ayala, Inc. since 2023 and at Biosight Therapeutics, Inc. since 2018.
Previously, he worked as the Medical Director at Bristol Myers Squibb Co. from 2012 to 2015, and as a Medical Director at BioMarin Pharmaceutical, Inc., Sonoma Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., and Proteolix, Inc. He also served as the Director of the Gene & Cell Therapy Unit at the Instituto Nacional de Salud Pública de México and the Instituto Nacional de Ciencias Medicas y Nutricion.
From 2016 to 2018, he was the Chief Medical Officer at Oncolytics Biotech, Inc. and later at Advaxis, Inc. He was also the Chief Medical Officer at Sellas Life Sciences Group Ltd.
from 2015 to 2016.
Additionally, he is currently pursuing a doctorate degree from the Universidad Nacional Autónoma de México.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/12/2022 | 47 ( 0,00% ) | 30 $ | 31/03/2024 |
Postes actifs de Andres Gutiérrez
| Sociétés | Poste | Début |
|---|---|---|
| ADVAXIS, INC. | Chief Tech/Sci/R&D Officer | 19/01/2023 |
Anciens postes connus de Andres Gutiérrez
| Sociétés | Poste | Fin |
|---|---|---|
| AYALA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 25/03/2024 |
| ONCOLYTICS BIOTECH INC. | Chief Tech/Sci/R&D Officer | 23/04/2018 |
Sellas Life Sciences Group Ltd.
 Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Chief Tech/Sci/R&D Officer | 01/09/2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2015 |
| Instituto Nacional de Salud Pública de México | Corporate Officer/Principal | - |
Formation de Andres Gutiérrez
| Universidad Nacional Autónoma de México | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| ONCOLYTICS BIOTECH INC. | Health Technology |
| SONOMA PHARMACEUTICALS, INC. | Health Technology |
| AYALA PHARMACEUTICALS, INC. | Commercial Services |
| Entreprise privées | 7 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
| Instituto Nacional de Salud Pública de México | |
Instituto Nacional de Ciencias Medicas y Nutricion
 Instituto Nacional de Ciencias Medicas y Nutricion Hospital/Nursing ManagementHealth Services Instituto Nacional de Ciencias Medicas y Nutricion operates hospitals. The private company is based in Mexico City, Mexico. | Health Services |
Old Ayala, Inc.
 Old Ayala, Inc. Pharmaceuticals: MajorHealth Technology Old Ayala, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel. | Health Technology |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Health Technology |
